<DOC>
	<DOCNO>NCT02083289</DOCNO>
	<brief_summary>The primary objective study compare safety , tolerability , mean change baseline diurnal intraocular pressure ( IOP ) ONO-9054 30 µg/mL ( 0.003 % ) latanoprost 0.005 % follow ocular instillation every evening 28 day .</brief_summary>
	<brief_title>A 28 Day Study ONO-9054 Ophthalmic Solution Subjects With Ocular Hypertension ( OHT ) Open-angle Glaucoma ( OAG )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Male female age 1885 ( inclusive ) confirm diagnosis OHT OAG Confirmed diagnosis bilateral OHT mild moderate chronic OAG Able undergo washout ocular drug An IOP ≥ 24 mmHg 8:00 AM ≥ 21 mmHg 10:00 AM least 1 eye ; &lt; 36 mmHg eye Day 5 Day 1 Central corneal thickness 500620 µm screen Day 5 eye Best correct visual acuity ( BCVA ) +0.7 Log Mar well Any history severe ocular trauma either eye time History angle closure ocular laser surgery within past 3 month refractive surgery procedure within past 6 month Screening Visit study eye ( ) Cataracts prevent observation photography fundus either eye</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>ONO-9054</keyword>
	<keyword>ocular hypertension ( OHT )</keyword>
	<keyword>Open angle-glaucoma ( OAG )</keyword>
	<keyword>Glaucoma</keyword>
	<keyword>Eye Diseases</keyword>
	<keyword>Mild moderate</keyword>
</DOC>